Completed PHASE3 INTERVENTIONAL 2-arm NCT00912093

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Icatibant for Subcutaneous Injection in Patients With Acute Attacks of Hereditary Angioedema (HAE)

Sponsor: Shire

Conditions Hereditary Angioedema

Interventions Icatibant Placebo

Updated 8 times since 2017 Last updated: Jun 3, 2021 Started: Jul 16, 2009 Primary completion: Oct 1, 2010 Completion: Oct 1, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hereditary Angioedema and is currently completed. Shire leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Alabaster, United States , Asheville, United States , Atlanta, United States , Bethlehem, United States , Birmingham, United States , Boston, United States , Budapest, Hungary , Campbelltown, Australia , Cape Town, South Africa and 49 more locations